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ABSTRACT
Our SNP-Chip data demonstrated 7/60 (12%) hepatocellular carcinoma (HCC) 
patients had PRL-1 copy number amplification. However, its biological functions and 
signaling pathways in HCC are deficient. Here, we investigated its oncogenic function 
and prognostic significance in HCC. PRL-1 protein levels were examined in 167 HCC 
samples by immunohistochemisty (IHC). The relationship of PRL-1 expression and 
clinicopathological features was assessed by correlation, Kaplan-Meier and Cox 
regression analyses. The oncogenic function of PRL-1 in HCC cells and its underlying 
mechanism were investigated by ectopic overexpression and knockdown model. PRL-
1 levels in primary HCC and metastatic intravascular cancer thrombus were also 
determined by IHC. PRL-1 levels were frequently elevated in HCC tissues (81%), 
and elevated expression of PRL-1 was significantly associated with more aggressive 
phenotype and poorer prognosis in HCC patients (p<0.05). Ectopic overexpression 
of PRL-1 markedly enhanced HCC cells migration and invasion. Furthermore, the 
oncogenic functions of PRL-1 were mediated by PI3K/AKT/GSK3β signaling pathway 
through inhibiting E-cadherin expression. Finally, PRL-1 protein levels in metastatic 
cancer thrombus were higher than that in primary HCC tissues (p<0.05). These data 
highlight the oncogenic function of PRL-1 in HCC invasion and metastasis implicating 
PRL-1 as a potential prognostic marker as well as therapeutic target in HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common cancer worldwide and the third most common 
cause of cancer mortality [1,2]. More than 75% of 
HCC patients develop recurrence and/or metastasis 
within 5 years after surgery becoming the main cause 
of death for these individuals [3]. Reversible tyrosine 
phosphorylation is critical for regulating the signaling 
pathways involved in tumor cell adhesion, invasion, and 
metastasis, It is governed by the balance between protein 
tyrosine kinases (PTKs) and protein-tyrosine phosphatases 
(PTPs) [4]. Compared with the large family of PTKs, 
PTPs superfamily has been less intensively studied. The 
phosphatase of regenerating liver (PRL) subgroup of 
PTPs, a unique class of prenylated phosphatases, had 
received much attention since PRL-3 was found to be the 
only gene consistently overexpressed in all 18 metastatic 
colorectal cancers [5]. 
Among the PRL family, PRL-3 is the most 
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thoroughly investigated and its upregualtion is associated 
with progression and metastasis of several types of human 
cancer, including colorectal, breast, and gastric tumors 
[6-8]. PRL-3 shows promise as a potential biomarker of 
cancer prognosis as well as therapeutic target of cancers 
[9]. In contrast, the role in cancer of PRL-1 and PRL-
2, the other two members of PRLs family, is less well 
studied. PRL-1 phosphatase (also known as PTP4A1) 
was originally identified as an immediate early gene in 
regenerating liver after partial hepatectomy and mitogen-
stimulated cells [10,11]. Subsequent studies revealed that 
PRL-1 expression was elevated in several tumor cell lines, 
and ectopic overexpression of PRL-1 enhanced tumor cell 
proliferation [12], clonogenic growth in soft agar [11], 
as well as migration and invasion [13,14]. Importantly, 
the expression of PRL-1 enhanced metastatic potential 
of tumors. Zeng et al [13] demonstated that following 
the injection of Myc-PRL-1-expressing CHO cells into 
the tail vein of mice, induced lung metastases occurred, 
whereas control cells did not form lung tumors. A similar 
experiment [6] found that both the number and volume 
of hepatic metastatic foci decreased significantly in 
the mice injected with PRL-1-small interfering RNA-
treated DLD-1 cells as compared to control cells. These 
results suggested an oncogenic role for PRL-1 in cancer 
progression and metastasis.
Functionally, PRL-1 phosphatase has been linked 
to several pathways [15], including the regulation of 
diverse focal adhesion components (e.g. p130Cas, Src, 
FAK) [16,17], Rho GTPases family [14], ERK1/2 [18] 
as well as MMPs [19]. However, the fuction of PRL-1 in 
cancer cells including liver cancer, is poorly understood, 
even though PRL-1 phosphatase was first discovered in 
regenerating liver tissue. In this report, we show that (i) 
PRL-1 is very frequently amplified and overexpressed in 
hepatocellular carcinoma; (ii) PRL-1 represses E-cadherin 
expression associated with enhancing hepatoma cells 
migration and invasion in concert with activating the 
PI3K/AKT signaling pathway; (iii) Elevated level of 
PRL-1 is associated with intravascular metastasis and 
an independent prognostic factor for poor survival for 
patients with HCC.
RESULTS
Copy number amplification and higher protein 
levels of PRL-1 are frequently detected in HCC 
tissues
DNA copy number analysis of HCC samples showed 
that 7/60 (12%) samples had amplification of Chr6:q12, in 
two cases which had a narrow region of Chr6:q12 with 
high DNA copy number. The common minimum amplified 
region (CMAR) of chr6 (q12) encompassed only the 
PRL-1 and PHF3 genes (Figure 1A). Moreover, PRL-1 
is expressed as an immediate-early gene in regenerating 
liver [11], prompting us to focus further on this gene. 
Protein expression level of PRL-1 was examined in 
167 HCC specimens and 7 normal liver samples by 
IHC. The immunohistochemical staining intensity was 
divided into low, medium and high groups (Figure 1B). 
Compared with normal liver tissues, levels of PRL-1 were 
significantly higher in HCC samples. 65% (109/167) of 
Table 1: Correlation of PRL-1 Expression Levels with 
Clinicopathological Status in HCC Patients
Variablesa
PRL-1
P-valueb
low/medium high
Age(years) 0.100
<45 15 42
≥45 43 67
Gender 0.885
male 49 93
female 9 16
AFP(ug/L) 0.122
<400 37 56
≥400 20 51
HBV infection 0.886
(-) 7 14
(+) 51 95
Tumor size(cm) 0.399
>5 17 39
≥5 41 70
cirrhosis 0.013*
(-) 20 19
(+) 38 90
TNM stage 0.035*
I 33 43
II/III 25 65
Histological 
grade 0.534
I 21 35
II 24 38
III 12 30
cancer thrombus 0.048*
(-) 38 54
(+) 20 55
aCases with missing data were not included for analysis
bp-value by Chi-square test
AFP, alpha-fetoprotein; HBV, hepatitis B virus; TNM, 
tumour-node-metastasis
*p<0.05
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Figure1: Copy number analysis, expression levels and prognostic value of PRL-1 in patients with HCC. A, 7 cases had 
amplification of Chr6:q12 (black arrow). B. Different immunohistochemical intensity showing that (a) represents low expression in normal 
liver tissue and (b-d) represent low, medium, and high expression in HCC tissues, respectively. Magnification: x200. C, Expression status 
of PRL-1 was determined in 7 normal liver and 167 HCC samples by IHC. PRL-1 was significantly overexpressed in HCC tissues (Kruskal 
Wallis Test, p<0.001). D, Kaplan–Meier survival analysis of PRL-1 expression in HCC patients (p=0.0136).
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HCC cases had high staining, 15% (25/167) with medium 
staining and 20% (33/167) low staining (Figure 1C). In 
contrast, all 7 non-neoplastic liver tissues displayed low 
immunohistochemical staining. Integrative analysis of 
both our SNP-Chip and protein expression data strongly 
suggests that PRL-1 may function as an oncogene in HCC.
High-level protein expression of PRL-1 in HCC 
is associated with an aggressive and/or poor 
prognostic phenotype
The clinicopathological and prognostic significance 
of PRL-1 protein levels in HCC patients were examined 
using correlation, Kaplan-Meier and Cox regression 
analyses. High PRL-1 protein level was significantly 
correlated with a more aggressive tumor phenotype as 
measured by TNM stage as well as cancer thrombus 
(p<0.05, Table1). The median overall survival (OS) 
of high-level PRL-1 expression group (10.07 months) 
was much shorter than the OS of the low/medium-level 
group (26.07 months) (p=0.0136, Figure 1D). Univariate 
Cox regression analysis also indicated those patients 
whose HCC had high expression of PRL-1 had shorter 
OS (p=0.012, Table 2). Furthermore, multivariate Cox 
regression analysis revealed that high-level expression of 
PRL-1 is an independent prognostic factor for poor OS of 
patients with HCC (p=0.017, Table 2).
Exogenous overexpression of PRL-1 enhanced 
migration and invasion of hepatoma cells in vitro
The above observations prompted us to explore 
the potential biological function of PRL-1 in HCC 
progression. HCC cell lines were stably transfected with 
pMSCV-HA-PRL-1 expression vector (Figure 2A, B). 
Those cells with forced expression of PRL-1had greaten 
ability to migrate compared to control (ctrl) cells as 
measured by both a wound-healing assay and a Matrigel 
invasion assays using Huh7-HA-PRL-1 and SK-hep1-HA-
PRL-1 cells versus vector contro cells (p<0.01, Figure 2C, 
D).
PRL-1 inhibits E-cadherin expression in HCC cell 
lines and has inverse correlation with E-cadherin 
expression in HCC tissues
Endothelial-mesenchymal transition (EMT) provides 
cancer cells with invasive and metastatic properties [20]. 
We investigated whether PRL-1 may be involved in 
regulation of EMT in HCC. Expression of E-cadherin 
was down-regulated after ectopic overexpression of PRL-
1 in Huh7 and SK-hep1 cells (Figure 3A). In contrast, 
silencing PRL-1 expression by small interfering RNA 
(siRNA) caused a marked increase of E-cadherin mRNA 
Table2: Univariate and multivariate analysis of factors 
associated with overall survival of patients with 
hepatocellular carcinoma
Vavirable cases number HR(95%CI)
p 
value
Univariate 
analysis
Age(years) 0.049
<45 vs ≥45 50/90 0.690(0.477-0.999)
Gender 0.014
Male vs Female 118/22 1.814(1.128-2.915)
AFP(ug/L) 0.040
<400 vs ≥400 77/63 1.454(1.018-2.078)
HBV infection 0.772
(-) vs (+) 19/121 1.098(0.657-1.834)
Tumor size(cm) 0.003
<5 vs ≥5 44/96 1.807(1.221-2.675)
Cirrhosis 0.211
(-) vs (+) 36/104 1.311(0.858-2.003)
TNM stage 0.000
I vs II/III 65/75 2.046(1.426-2.937)
Histological 
grade 0.004
I/II vs III 102/38 1.798(1.203-2.687)
Cancer thrombus 0.000
(-) vs (+) 71/69 2.038(1.420-2.925)
PRL-
1(expression) 0.012
Low/midum vs 
High 51/89
1.629(1.116-
2.377)
Multivariate 
analysis
Gender 0.004
Male vs Female 118/22 2.026(1.249-3.286)
PRL-
1(expression) 0.017
Low/Medium vs 
High 51/89
1.584(1.084-
2.316)
TNM stage 0.000
I vs II/III 65/75 2.318(1.478-3.091)
HRs(95% CI) and p values were calculated using 
univariate or multivariate Cox proportional hazard 
regression in 140 cases
AFP, alpha-fetoprotein; HBV, hepatitis B virus; TNM, 
tumour-node-metastasis
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levels in the HepG2 cell line (p<0.05, Figure 3A). 
Congruent with the RNA data, western blots showed that 
E-cadherin protein levels decreased after reintroduction of 
PRL-1 in Huh7 and SK-hep1 cell lines, and knockdown 
of PRL-1 expression caused a marked enhancement of 
E-cadherin protein level in Huh7 cells (Figure 4A, B, C). 
Furthermore, immunofluorescence assay confirmed that 
forced expression of PRL-1 down-regulated E-cadherin 
protein level in Huh7 and SK-hep1 HCC cell lines (Figure 
3B). Taken together, these results indicate that PRL-1 
regulated E-cadherin expression in HCC cells at both the 
mRNA and protein levels.
The relationship between PRL-1 and E-cadherin 
expression was further evaluated by IHC in 167 clinical 
HCC samples. A total of 83% (90/109) of HCC samples 
with high PRL-1 expression level displayed low 
E-cadherin expression. Likewise, 44% (17/39) of cases 
with high level of E-cadherin had low expression level 
of PRL-1. Correlation analysis found that a significant 
negative correlation existed between expression of PRL-1 
and E-cadherin in HCC [p=0.002 (Spearman’s rho test), 
Figure 3C]. Representative case No.64 showed high PRL-
1 and low E-cadherin expression levels; and vice versa 
was noted in case No.54. Taken together, these results 
suggest that PRL-1 regulates the expression of E-cadherin 
in HCC.
PRL-1 inhibits the expression of E-cadherin in 
HCC by activating PI3K/AKT/GSK3β signaling 
pathway
PI3K/AKT signaling pathway modulates EMT 
[20], prompting us to examine this pathway in HCC cell 
lines using western blot assay. Exogenous overexpression 
of PRL-1 in Huh7 and SK-hep1 cell lines enhanced 
phosphorylation of AKT at Ser474,which resulted in 
increase phosphorylation of GSK3βand elevated levels 
of Snail expression and as previously noted, decreased 
E-cadherin expression (Figure 4A, B). In contradistinction, 
Figure2: Exogenous expression of PRL-1 promotes hepatoma cell migration and invasion. A and B, PRL-1 and empty 
vector stably-transfected HCC cell lines were successfully constructed by pMSCV-PIG retrovirus infection. C, Ectopic overexpression 
of PRL-1 remarkbely enhanced Huh7 cells migration. D, PRL-1 stably-transfected Huh7 and SK-hep1 cells showed significantly higher 
invasive capacity compared with their respective control cells.
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silencing of PRL-1 protein level using siRNA interference 
caused down-regulation of expression of p-AKT(Ser474), 
p-GSK3β(Ser9) and Snail transcriptional factor (Figure 
4C).
To explore further whether PI3K/AKT signaling 
pathway is involved in PRL-1-mediated inhibition 
of E-cadherin expression, ZSTK474, a novel 
phosphatidylinositol 3-kinase (PI3K) inhibitor was 
utilized. Decrease of p-AKT (Ser474) after exposure of the 
cells to ZSKT474 reduced expression of p-GSK3β (Ser9) 
and Snail and restored E-cadherin expression (Figure 4D). 
Collectively, these observations support that PRL-1 can 
enhance the PI3K/AKT signaling pathway resulting in a 
reduction of E-cadherin expression in HCC cells.
PI3K/AKT signals are potentially involved 
in PRL-1-enhanced HCC cell migration and 
invasion
To evaluate whether PI3K/AKT signals could 
mediate the invasive properties of PRL-1 in HCC, stably 
transfected Huh7-HA-PRL-1 cells were treated with 
PI3K inhibitor, ZSTK474 (10 uM) which abrogated the 
enhanced migration mediated by PRL-1 in HCC cells as 
measured by the wound-healing assay (Figure 4E) and the 
Figure3: PRL-1 represses the expression of E-cadherin at both the mRNA and protein levels and negatively correlates 
with E-cadherin expression in clinical HCC samples. A, Reintroduction of PRL-1 markedly inhibited E-cadherin expression at 
mRNA level in Huh7 and SK-hep1 cell lines; the mRNA level of E-cadherin was elevated substantially after Knockdown PRL-1 expression 
in HepG2 cell line by small interfering RNA (siRNA). B, Immunofluorescence was used to compare the expression levels of E-cadherin 
between PRL-1 stably-transfected cell lines and their respective control cell lines. PRL-1 (green signal) significantly suppressed E-cadherin 
(red signal) expression in Huh7 and SK-hep cell lines. Magnification: x400. C, PRL-1 expression inversely correlates with E-cadherin 
expression in HCC tissues as measured by IHC. (a), two examples of association of PRL-1 with E-cadherin expression. The upper panels, 
low magnification (x100); the lower panels, high magnification (x200). (b), Correlation analysis reveals that PRL-1 is significantly 
asscociated with E-cadherin expression (p=0.002)
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matrigel invasion assay (p<0.01, Figure 4F). These results 
provide evidence that an active PI3K/AKT signaling 
pathway can mediate the invasive activities of hepatoma 
cells that overexpress PRL-1.
PRL-1 is potentially involved in metastatic 
process of primary liver cancer
Tissue sections of 13 HCC cases with intravascular 
cancer thrombus were analyzed by IHC. A total of 10/13 
(77%) of cases displayed high IHC staining of PRL-1 in 
the metastatic intravascular cancer thrombus. McNemar 
test showed that that IHC staining intensity of PRL-1 is 
stronger in metastatic lesion than in primary liver cancer 
(p=0.031). Three representative examples showed the 
strong IHC staining of PRL-1 in the intravascular cancer 
thrombus (Figure 5A). These findings are consistent with 
PRL-1 playing an important role in the metastatic process 
of primary HCC.
DISCUSSION
A powerful approach to discover key genes playing 
causal roles in tumorigenesis is to identify genomic 
regions that undergo frequent alterations in human cancers 
[21]. High-density SNP-Chip arrays allow rapid detection 
Figure4: PRL-1 suppresses E-cadherin expression through PI3K/AKT signaling pathway and PI3K/AKT signals 
mediate PRL-1-enhanced migration and invasion in HCC cells. A and B, Exogenous overexpression of PRL-1 enhanced 
phosphorylation of AKT at Ser474, inactivated GSK-3β at Ser9, upregulated expression of Snail transcriptional factor, and downregulated 
E-cadherin expression in Huh7 and SK-hep1 cell lines by Western blot assay. C, Knockdown PRL-1 expression by small interfering 
RNA approach inhibited p-AKT (Ser474), activated GSK-3β(Ser9), downregulated Snail expression, and reversed E-cadherin expression. 
D, Treatment of Huh7-HA-PRL-1 cells with PI3K inhibitor, ZSTK474, suppressed phosphorylation of AKT at Ser474, stabilized GSK-3β, 
reduced Snail expression, and restored the experssion of E-cadherin. ZSTK474 (10uM) markedly suppressed PRL-1-induced migration in 
SK-hep1 cells (E) and invasion in Huh7 and SK-hep1 cells (F). Scale bar: 20 um.
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of copy number changes in small regions of the cancer 
genome DNA, including amplifications, deletions, and 
acquired uniparental disomy (AUPD) [22,23]. In some 
cases, focal somatic copy number alterations (SCNAs) 
have led to the identification of cancer-causing genes [24-
26]. Our high-density SNP-Chip arrays showed that seven 
of 60 HCC patients had PRL-1 copy number amplification. 
In addition, we observed by IHC that upregulation of 
expression of PRL-1 protein was a frequent event in HCC 
tissues. Together, the data implicated PRL-1 as a potential 
cancer-related gene in HCC.
Elevated PRL-1 levels were significantly associated 
with higher TNM stages and intravascular cancer thrombus 
in HCC, indicating a more aggressive tumor phenotype. 
Kaplan-Meier and Cox regression analysis suggested 
that increased expression of PRL-1 was an independent 
indicator of short post-surgical OS for patients with HCC. 
Functional analysis of PRL-1 in HCC cells demonstrated 
that overexpression of PRL-1 dramatically enhanced 
hepatoma cells migration and invasion.
Recurrence and metastasis are two related hallmarks 
of cancer [27]. Both are major causes of HCC-related 
mortility. Thus, identification the underlying molecular 
mechanisms are critical. EMT, is strongly hypothesized 
as a driver of cancer progression and metastasis [28]. 
This process results in the loss of epithelial properties 
including cell-cell adhesion and baso-apical polarity, and 
the gain of mesenchymal properties, which facilitates cell 
motility and invasion [29]. Among the markers of EMT, 
decrease of expression of E-cadherin has been recognized 
as a central molecule. Furthermore, loss of E-cadherin 
is correlated with tumor progression and metastasis in 
a variety of human cancers [30]. Our experimental data 
showed that exogenous expression of PRL-1 depressed 
E-cadherin expression level, while silencing of PRL-1 
levels elevated E-cadherin expression at both mRNA and 
Figure5: Comparison of PRL-1 expression in primary HCC and metastatic intravasular cancer thrombus by IHC. A, 
Three illustrations showing the immunohistochemical staining in metastatic cancer thrombus (blue arrows) is stronger than that in primary 
lesion (black arrow). The upper panels, magnification (x100) and the lower panels, magnification (x200). B, A schematic diagram indicating 
that intravasular cancer embolus had higher PRL-1 expression than primary HCC (p=0.031). ▲, primary lesion. ●, metastatic intravasular 
cancer thrombus.
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protein levels of HCC cells. Importantly, we found that 
expression levels of PRL-1 were significantly inversely 
correlated with expression levels of E-cadherin in HCC 
using tissue microarrays. These observations suggest 
that PRL-1 potentially accelerates liver cancer cells 
progression through inhibiting E-cadherin expression.
We dissected the molecular signaling pathway 
associated with ability of PRL-1 to repress expression of 
E-cadherin. Reintroduction of PRL-1 in Huh7 and SK-
hep1 HCC cell lines caused phosphorylation of AKT at 
ser474, which subsequently inactivated GSK-3β at ser9 
and elevated transcriptional factor Snail expression. 
Snail is known to be able to down-regulate transcription 
of E-cadherin. Consistent with this PRL-1 signaling 
pathway, the knockdown of PRL-1 expression in Huh7 
cell line inhibited phosphorylation of AKT at ser473, 
activated GSK-3β at ser9, and decreased Snail expression, 
resulting in restoration of E-cadherin expression. In 
addition, treatment of PRL-1 stably-transfected HCC 
cells (Huh7) with PI3K inhibitor ZSTK474 remarkably 
repressed activities of phosphorylation of AKT at ser474, 
restored GSK-3βactivities, inhibited Snail expression, 
rescued the expression of E-cadherin, as well as repressed 
cells migration and invasion. In summary, elevated 
levels of PRL-1 in HCC cells activate the PI3K/AKT 
signaling pathway resulting in Snail repression E-cadherin 
transcription and enhanced migration and invasion of 
HCC cells. Furthermore, intravascular HCC thrombi had 
high PRL-1 expression, consistent with elevated PRL-1 
acting as a pro-metastatic factor in HCC. Our data also 
suggest that PRL-1 may be an useful prognostic marker 
and/or an effective therapeutic target for HCC patients.
MATERIALS AND METHODS
DNA preparation and high-density SNP-Chip 
analysis
K-phenol-chloroform extraction method was used 
to extract DNA from HCC samples. Written informed 
consent for research use of all of these samples was 
obtained prior to surgery, according to a protocol approved 
by the institutional ethics committee. SNP-Chips for 
human 50k XbaI / 250k Nsp arrays were used for this 
study (SNP-Chip, Affymetrix, Santa Clara, CA, USA), as 
previous described [22,23]. The ArrayExpress accession 
number is E-MEXP-1330.
Tissue specimens and tissue microarray
HCC and the adjacent normal liver tissue samples 
were obtained with informed consent under institutional 
review board-approved protocols. The samples were 
collected between June 2000 and September 2007 at the 
Sun Yat-sen Memorial Hospital, Sun Yat-Sen University 
(Guangzhou, China). The HCC cases selected were based 
on a clear pathological diagnosis, follow-up data; and 
the patients had not received previous local or systemic 
treatment. Tumour stage was defined according to the 2002 
American Joint Committee on Cancer/International Union 
Against Cancer tumour-node-metastasis classification 
system. This study was approved by the institute 
research ethics committee of the Sun Yat-sen Memorial 
Hospital, Sun Yat-Sen University. Tissue microarray was 
constructed by He C. et al [31].
Cell cultures and reagents
Three HCC cell lines (i.e., HepG2, Huh7 and SK-
hep1) and 293T cell line were cultured in Dulbecco’s 
Modification of Eagle’s Medium (DMEM; Gibco, 
Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum (FBS; Gibco, Carlsbad, CA, USA). The 
stably transfected cell lines were cultured in DMEM 
supplemented with 10% FBS and 1 μg/mL puromycin 
(Sigama-Aldrich, St.louis, MO, USA). All cells were 
maintained at 37oC in a humidified incubator with 5% 
CO
2
.
Immunohistochemistry (IHC)
The immunohistochemical study of PRL-1 and 
E-cadherin was performed using a standard two-step 
technique. Paraffin sections were dried for 20min at 68oC, 
dewaxed in xylene, rehydrated through graded alcohol, 
and immersed in 3% hydrogen peroxide for 15 min to 
block endogenous peroxidase activity. An antigen retrieval 
process was accomplished using hyperbaric heating (HH) 
repair with 10 mM citrate buffer (pH 6) for 3 min. The 
slides were incubated with 5% normal goat serum at room 
temperature for 30 min to reduce nonspecific reaction. 
Subsequently, the slides were incubated overnight at 
4oC with either rabbit polyclonal antibody against PRL-
1 (1:100; Abgent, USA) or rabbit monoclonal antibody 
against E-cadherin (1:100; Cell Signaling Technology, 
USA). After rinsing three times with 0.01 mol ⁄ L 
phosphate-buffered saline (PBS; pH = 7.4) for 10 min, 
the detection of the primary antibody was achieved 
by addition of a secondary antibody (Envision; Dako, 
Glostrup, Denmark) for 1 h at room temperature, and 
stained with DAB (3,3-diaminobenzidine) after washing in 
PBS again. Finally, the sections were counterstained with 
Mayer’s hematoxylin, dehydrated, and mounted. PBC 
replaced primary antibody as a negative control.
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Construction of pMSCV-HA-PRL-1 plasmid
PCR fragments of HA-PRL-1 were inserted into 
BgiII and XhoI sites of the pMSCV-PIG vector provided 
by Dr. Mendel [32].
Production of PRL-1 stable HCC cell lines
HepG2, Huh7, and SK-hep1 HCC cell lines were 
stably infected using pMSCV-PIG vector containing the 
human PRL-1 gene. HEK293T packaging cells were 
transfected with the appropriate retroviral construct using 
Lipofectamine 2000 (Invitrogen). Culture supernatants 
were collected 36 to 60 hours after transfection and 
filtered. Target cells were infected with the filtered viral 
supernatants in the presence of 6 μg/mL Polybrene for 48 
hours, after which the medium was changed. Following 
infection, cells were selected with 4 μg/mL puromycin for 
2 weeks, and the resistant population was used for cellular 
assays.
Wound healing and invasion assays
Cell migration was assessed by measuring the 
movement of cells into a scraped, acellular area created 
by the tip of a 200 ul pipette, and the degree of “wound 
closure” was observed after 24h and photographed under 
a microscope. We measured the fraction of cell coverage 
compared to initiate gap and defined it as the migration 
rate. For invasion assays, 105 cells were added to a 
Matrigel invasion chamber (BD Biosciences, New Jersey, 
USA) present in the insert of a 24-well culture plate. 
10% FBS was added to the lower chamber as a chemo-
attractant. After either 10 h (SK-hep1 cells) or 12 h ( Huh7 
cells), the non-invading cells were gently removed with a 
cotton swab. Invasive cells, located on the lower side of 
the chamber, were fixed with 4% paraformaldehyde (PFA) 
and stained with crystal violet, air dried and photographed. 
For colorimetric assays, the samples were treated with 600 
ul 33% acetic acid, and the absorbance was measured at 
570 nm with a spectrophotometer (Spectramax M5).
RNA isolation and quantitative real-time PCR
Total RNA was extracted with TRIzol reagent 
(Invitrogen, Carlsbad, California, USA). cDNA was 
synthesized with the Prime Script RTase (Takara, Inc) 
according to the manufacturer’s instructions. Real-
time PCR for PRL-1, E-cadherin, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH, an internal 
control) was performed on a LightCycler 480 system 
(Roche) using Premix Ex Taq (Takara, Inc) according 
to the manufacturer’s instructions. Following 
primer pairs were used for each reaction: PRL-1, 
5’-ACCAATGCGACCTTAAACAAA-3’ (forward) 
and 5’-AATCTGGTTGGATGGTGGTG-3’ (reverse); 
E-cadherin, 5’-CGTCCTGGGCAGAGTGAA-3’ 
(forward) and 5’-GGCGTAGACCAAGAAATGGA-3’ 
(reverse); GAPDH, 5’-AGCCACATCGCTCAGACAC-3’ 
(forward) and 5’-GAATTTGCCATGGGTGGA-3’ 
(reverse).
RNA interference
Short interfering RNA specifically against PRL-
1 [12,33] and the corresponding scrambled siRNA 
(GenePharma, Shanghai, China) were transfected into 
HCC cells in six-well plates using X-treme GENE siRNA 
Transfection Reagent (Roche, German) according to the 
manufacturer’s instructions. Confirmation of silencing of 
target gene was measured by western blotting 48h post-
transfection.
Western blot assay
Cells were harvested and lysed in cell lysis buffer 
(50 mM Tris-HCl [pH 7.4], 250 mM NaCl, 0.1% NP-
40, 5 mM EDTA, 2 ug/ml leupeptin, 2 ug/ml aprotinin, 
4 mM Prefabloc SC, and protein inhibitor cocktail). 
Each 25 ug aliquot of denatured protein were separated 
by 10% SDS-PAGE, and then transferred onto a 0.22 um 
polyvinylidene difluoride membranes (Millipore). After 
completing protein transfer, the membrane was blocked in 
5% (w/v) skimmed milk in TBST and incubated overnight 
at 4oC with the rabbit polyclonal antibody (IgG) against 
AKT, p-AKT (Ser474), GSK3β, p-GSK3β (Ser9), Snail, 
E-cadherin, PRL-1, and HA, respectively. The blots 
were detected by the secondary antibody, horseradish 
peroxidase (HRP)-linked polyclonal goat anti-rabbit IgG 
and visualized with SuperSignal West Dura (Thermo). 
GAPDH served as an internal loading control. Except 
that PRL-1 antibody was obtained from Abgent, all the 
other antibodies were purchased from Cell Signaling 
Technology. All antibodies were diluted to 1:1000.
Immunofluorescence analysis
Cells were grown in glass-bottom dishes (Nest, 
Wuxi, China) to 50-70% confluence, washed three 
times with PBST, fixed in 4% PFA and processed for 
immunofluorescence staining. For IF staining, cells were 
first incubated with primary mouse anti-HA antibody 
(1:400 dilution) and rabbit anti-E-cadherin (1:200 
dilution) overnight at 4°C. After thorough washing, cells 
underwent 1 hour incubation with fluorescence-conjugated 
secondary antibody (Pyld-conjugated goat anti-mouse, 
APC-conjugated goat anti-rabbit) at room temperature. 
Subsequently, cells were washed and stained with 0.5 
Oncotarget3695www.impactjournals.com/oncotarget
ug/ml DAPI (Vector Laboratories, Burlingame, CA). 
Finally, cells were washed three times with PBST and 
photographed under a laser confocal microscope (Zeiss 
LSM710, German).
Statistical analysis
Statistical analysis was performed using a SPSS 
software package (SPSS Standard version 13.0, SPSS Inc). 
Differences between variables were assessed by the Chi-
square test. Survival analysis of patients with HCC was 
calculated by Kaplan-Meier analysis. A log rank test was 
used to compare different survival curves. Multivariate 
survival analysis was performed on all parameters that 
were found to be significant in univariate analysis using 
the Cox regression model. Data derived from cell-line 
experiments are presented as mean±SD (X±SD) and 
assessed by a two-tailed Student t test. p Values <0.05 
were considered significant.
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